The ESMO Breast Cancer Virtual Meeting took place from 5–8 May 2021. Global experts in the breast cancer field came together online to present on the most recent advances, including updates from immunotherapy trials and the latest novel therapeutic targets.
View all videos

ESMO Breast 2021

The European School of Medical Oncology Breast Cancer Virtual Congress 2021
05–08 May 2021 | Virtual Meeting

ESMO Breast 2021

The European School of Medical Oncology Breast Cancer Virtual Congress 2021
05–08 May 2021 | Virtual Meeting
The ESMO Breast Cancer Virtual Meeting took place from 5–8 May 2021. Global experts in the breast cancer field came together online to present on the most recent advances, including updates from immunotherapy trials and the latest novel therapeutic targets.
View all videos

Latest videos from ESMO Breast 2021

View all
3:22
PTEN protein and gene expression as a biomarker in breast cancer
Nicola Fusco • 13 May 2021
3:15
Brain metastases in HER2+ breast cancer
Volkar Mueller • 12 May 2021
2:38
Potential new drugs with activity in metastatic TNBC
Javier Cortés • 12 May 2021
5:55
Decision-making in metastatic HER2+ breast cancer
Lisa Carey • 29 Apr 2021

TNBC

View all
1:51
Optimal chemotherapy combinations in TNBC gBRCA subtypes
Sung-Bae Kim • 4 May 2021
5:53
Treating early-stage TNBC
Rebecca Dent • 29 Apr 2021
1:25
Dato-DXd: a new ADC on the block
Sara Tolaney • 12 May 2021
2:57
IO-IO combinations in metastatic TNBC
Marleen Kok • 12 May 2021

Metastatic Breast Cancer

View all
1:39
Abemaciclib for HR+/HER2- advanced or metastatic breast cancer
Ahmad Awada • 6 May 2021
2:10
Treating CNS metastases in HER2+ breast cancer
Thomas Bachelot • 21 Apr 2021
1:56
Treating HER2+ breast cancer with brain metastases
Erika Hamilton • 11 May 2021
7:16
E-cadherin inactivation by Trop-2 drives metastases in TNBC
Saverio Alberti • 21 Apr 2021

Immuno-Oncology

View all
4:08
ROSALINE: targeting ROS1 in combination with ET for breast cancer
Elisa Agostinetto • 20 Apr 2021
4:01
Trastuzumab deruxtecan: a promising agent for treating HER2-low breast cancer?
Paolo Tarantino • 27 Apr 2021
1:25
Dato-DXd: a new ADC on the block
Sara Tolaney • 12 May 2021
6:51
ADCs for HER2+ and HER2-low breast cancer
Rupert Bartsch • 11 May 2021

Breast Cancer Podcasts

Sequencing HER2-targeting therapies in the metastatic breast cancer space
The Breast Cancer Sessions: a focus on the St. Gallen Consensus
Predictive and prognostic biomarkers in breast cancer
SABCS 2020 highlights: immunotherapy, novel agents & trial updates

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals